

07-20-01

#9
08-25-

GP/1614/



SRL 6109
PATENT

TECH CENTER 1600/2900

JUL 26 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Richard A. Mueller, et al.
Serial No. 09/249,220
Filed February 12, 1999
Confirmation No. 9695
For USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS
VIRUS INFECTIONS

July 19, 2001

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,
SIR:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit the attached PTO 1449 for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

The references listed on the attached PTO-1449 are being submitted in parent application Serial No. 09/023,401 and, therefore, in accordance with MPEP 609, are not being provided at this time.

A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement.

Respectfully submitted,

John K. Roedel, Jr., Reg. No. 25,914
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

00000000 00000000 00000000

00 0000

000000 00